IPILIMUMAB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN AS FIRST-LINE TREATMENT IN EXTENSIVE DISEASE-SMALL CELL LUNG CANCER (ED-SCLC): RESULTS FROM A PHASE 2 TRIAL

被引：0
|
作者：
Reck, Martin [1 ]
Bondarenko, Igor [2 ]
Luft, Alexander [3 ]
Serwatowski, Piotr
Barlesi, Fabrice [4 ]
Chacko, Raju [5 ]
Sebastian, Martin [6 ]
Siegel, Jonathan [7 ]
Cuillerot, Jean-Marie [7 ]
Lynch, Thomas [8 ,9 ]
机构：
[1] Hosp Grosshansdorf, Dept Thorac Oncol, Grosshansdorf, Germany
[2] City Clin Hosp, Kiev, Ukraine
[3] Leningrad Reg Clin Hosp, St Petersburg, Russia
[4] Univ Aix Marseille 2, Assistance Publ Hop Marseille, Marseille, France
[5] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India
[6] Johannes Gutenberg Univ Med Ctr, Dept Hematol Oncol & Pneumol, Mainz, Germany
[7] Bristol Myers Squibb Co, New York, NY 10154 USA
[8] Yale Canc Ctr, Dept Oncol, New Haven, CT USA
[9] Smilow Canc Hosp, New Haven, CT USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：S310 / S311
页数：2
相关论文
共 50 条
  • [21] Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC).
    Cho, Daniel C.
    Mahipal, Amit
    Dowlati, Afshin
    Chow, Warren Allen
    Segal, Neil Howard
    Chung, Ki Y.
    Schneider, Bryan J.
    Nemunaitis, John J.
    Razak, Albiruni Ryan Abdul
    Tsai, Frank Yung-Chin
    Balmanoukian, Ani Sarkis
    Bazhenova, Lyudmila
    Xiao, Feng
    Angra, Natasha
    Abdullah, Shaad Essa
    Luke, Jason J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Phase I trial of sagopilone in combination with cisplatin as 1st-line therapy in patients with extensive-disease small-cell lung cancer (ED-SCLC)
    Christoph, D. C.
    Gauler, T. C.
    Gamarra, F.
    Fuhr, H. G.
    Fischer, J. R.
    Gonschorek, C.
    Frickhofen, N.
    Huber, R. M.
    Schuler, M.
    Eberhardt, W. E. E.
    EJC SUPPLEMENTS, 2009, 7 (02): : 542 - 542
  • [23] Phase II trial of huKS-IL2 with cyclophosphamide (CTX) in patients with extensive disease small-cell lung cancer (ED-SCLC)
    Gladkov, Oleg
    Biakhov, Mikhail
    Ramlau, Rodryg
    Serwatowski, Piotr
    Milanowski, Janusz
    Tomeczko, Janusz
    Komarnitsky, Philip B.
    Bernard, Laurence
    Kramer, Daniel
    Krzakowski, Maciej Jerzy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Phase II study of first line combination therapy with pegylated liposomal doxorubicin (PLD) and carboplatin in patients (pts) with extensive disease small cell lung cancer(ED SCLC)
    Vorobiof, D. A.
    Rapoport, B. L.
    Hlophe, H. S.
    Slabber, C. F.
    Alberts, A. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] TOTAL COST OF CARE AMONG PATIENTS WITH EXTENSIVE DISEASE SMALL CELL LUNG CANCER (ED-SCLC)
    Danese, M.
    Gleeson, M.
    Lubeck, D.
    Bobiak, S.
    VALUE IN HEALTH, 2017, 20 (05) : A358 - A358
  • [26] Phase II study of paclitaxel as first line treatment for patients with extensive stage small cell lung cancer (SCLC)
    Langley, RE
    Woll, PJ
    Davidson, N
    Libretti, V
    Smyth, JF
    Schipper, R
    Carmichael, J
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1040 - 1040
  • [27] A Phase II Trial of Carboplatin and Weekly Topotecan in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer
    Spigel, David R.
    Hainsworth, John D.
    Gandhi, Jitendra G.
    Gian, Victor G.
    Peyton, James D.
    West-Osterfield, Kimberly
    Clark, Bobby L.
    Vazquez, Elizabeth R.
    Jones, Suzanne F.
    Burris, Howard A., III
    Greco, F. Anthony
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (06) : 862 - 866
  • [28] A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Crawford, Jeffrey
    Swanson, Paul
    Schwarzenberger, Paul
    Sandler, Alan
    Prager, Diane
    Zhang, Kathy
    Freeman, Daniel J.
    Johnson, Carol W.
    Krishnan, Kartik
    Johnson, David
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (12) : 1510 - 1518
  • [29] Randomized, Phase III Trial of First-Line Figitumumab in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Advanced Non-Small-Cell Lung Cancer
    Langer, Corey J.
    Novello, Silvia
    Park, Keunchil
    Krzakowski, Maciej
    Karp, Daniel D.
    Mok, Tony
    Benner, Rebecca J.
    Scranton, Judith R.
    Olszanski, Anthony J.
    Jassem, Jacek
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (19) : 2059 - U109
  • [30] Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
    Lynch, Thomas J.
    Bondarenko, Igor
    Luft, Alexander
    Serwatowski, Piotr
    Barlesi, Fabrice
    Chacko, Raju
    Sebastian, Martin
    Neal, Joel
    Lu, Haolan
    Cuillerot, Jean-Marie
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) : 2046 - 2054
12345